UK Markets closed

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
13.350.00 (0.00%)
At close: 09:23AM CEST
Full screen
Previous close13.30
Open13.35
Bid0.00 x N/A
Ask0.00 x N/A
Day's range13.35 - 13.35
52-week range10.60 - 27.30
Volume38
Avg. volume163
Market cap113.475M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.17
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est29.00
  • EQS Group

    APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million 25.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million Medium-term revenue potential of Tonotec Lipid: EUR 5.0 million Medium-term revenue potential of AmloAtor: EUR 3.2 million Potential patient group of 750,000 peo

  • EQS Group

    APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities

    DGAP-News: APONTIS PHARMA AG / Key word(s): AGM/EGMAPONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities 12.05.2022 / 15:00 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majoritiesMonheim am Rhein, 12 May 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single

  • EQS Group

    APONTIS PHARMA continues strong profitable growth in Q1 2022

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim StatementAPONTIS PHARMA continues strong profitable growth in Q1 2022 10.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA continues strong profitable growth in Q1 2022 Single Pill revenues +40% to EUR 8.7 million remain main growth driver Single Pill revenue share increases to 61% (3M 2021: 57%) Total revenues grow faster than pharma sector by 31% to EUR 14.3 million EBITDA increas